This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Steel K, Feldman RG (1979) Diagnosing dementia and its treatable causes. Geriatrics 34: 79–88
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237–1239
Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ (1978) Pre- and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res 149: 447–481
Davis KL, Mohs RC (1982) Enhancement of memory processes in Alzheimer's disease with multiple dose intravenous physostigmine. Am J Psychiat 139: 1421–1424
Schwartz AS, Kohlstaedt EV (1986) Physostigmine effects in Alzheimer's diseases: Relationship to dementia severity. Life Sci 38: 1021–1028
Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia of the Alzheimer type. N Engl J Med 315: 1241–1245
Brufani M, Marta M, Pomponi M (1986) Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 157: 115–120
De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E (1989) The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 14: 971–977
Brufani M, Castellano C, Marta M, Oliverio A, Pagella PG, Pavone F, Pomponi M, Rugarli PL (1987) A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharm Biochem Behav 26: 625–629
Marta M, Castellano C, Oliverio A, Pavone F, Pagella PG, Brufani M, Pomponi M (1988) New analogs of physostigmine: alternative drugs for Alzheimer's disease? Life Sci 43: 1921–1928
Oliverio A, Castellano C, Iacopino C, Pavone F, Brufani M, Marta M, Pomponi M (1986) Effects of physostigmine derivatives on cerebral cholinergic functions and their possible use in Alzheimer disease. In: Biggio G, Spano PF, Toffano G and Gessa GL (eds) Modulation of Central and Peripheral Transmitter Function. Liviana Press, Padova, pp 305–309
Johnson CD, Russel RL (1975) A rapid, simple radiometric assay for cholinesterase, suitable for multiple determination. Anal Biochem 64: 229–238
Becker RE, Giacobini E (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological and therapeutic aspects. Drug Dev Res 12: 163–195
Becker RE, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V, Markwell S, Moriearty P, Parks R, Shillcutt SD, Unni LK, Vicori S, Womack C, Zec R (1990) Effects of metrifonate, a long-acting cholinesterase inhibitor in Alzheimer disease: Report of an open trial. Drug Dev Res 19: 425–434
Lawrence GD, Yatim N (1990) Extraction of physostigmine from biologic fluids and analysis by liquid chromatography with electrochemical detection. J Pharmacol Methods 24: 137–143
About this article
Cite this article
Unni, L.K., Hutt, V., Imbimbo, B.P. et al. Kinetics of cholinesterase inhibition by eptastigmine in man. Eur J Clin Pharmacol 41, 83–84 (1991). https://doi.org/10.1007/BF00280116
- cholinesterase inhibitor
- Alzheimer's disease
- adverse effects